Decoding the Proximity Paradigm: Integrating AI & Biology from Oral Degraders in I&I to RIPTAC-Driven Tumor-Selective Killing in Oncology
- Bridging the modality gap in I&I: decoding the distinct pharmacology of oral STAT6 degraders, small-molecule inhibitors, and therapeutic antibodies
- Engineering tumor-selective killing: decoding the AR-BRD4 RIPTAC mechanism with AI-guided modeling and mechanistic biology
- Navigating ffficacy and toxicity for next-gen molecules: integrating resistant cell panel profiling with full dose-response functional safety panel 77